258 related articles for article (PubMed ID: 35636521)
1. HDAC inhibitor quisinostat prevents estrogen deficiency-induced bone loss by suppressing bone resorption and promoting bone formation in mice.
Sun S; Xiu C; Chai L; Chen X; Zhang L; Liu Q; Chen J; Zhou H
Eur J Pharmacol; 2022 Jul; 927():175073. PubMed ID: 35636521
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of osteoclastogenesis by histone deacetylase inhibitor Quisinostat protects mice against titanium particle-induced bone loss.
Zhang L; Zhang L; You H; Sun S; Liao Z; Zhao G; Chen J
Eur J Pharmacol; 2021 Aug; 904():174176. PubMed ID: 34004213
[TBL] [Abstract][Full Text] [Related]
3. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine, a
Luo N; Zhang L; Xiu C; Luo X; Hu S; Ji K; Liu Q; Chen J
Food Funct; 2024 Feb; 15(4):2154-2169. PubMed ID: 38311970
[TBL] [Abstract][Full Text] [Related]
5. Bindarit Reduces Bone Loss in Ovariectomized Mice by Inhibiting CCL2 and CCL7 Expression via the NF-κB Signaling Pathway.
Yuan SG; Hu HL; Wang XJ; Yang JC; Zhou RP; Bai XC; Lai PL
Orthop Surg; 2022 Jun; 14(6):1203-1216. PubMed ID: 35470579
[TBL] [Abstract][Full Text] [Related]
6. Catalpol attenuates osteoporosis in ovariectomized rats through promoting osteoclast apoptosis via the Sirt6-ERα-FasL axis.
Chen S; Jin J; Xu Z; Han H; Wu L; Li Z
Phytomedicine; 2024 Jan; 123():155262. PubMed ID: 38100921
[TBL] [Abstract][Full Text] [Related]
7. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
8. Anti-perimenopausal osteoporosis effects of Erzhi formula via regulation of bone resorption through osteoclast differentiation: A network pharmacology-integrated experimental study.
Qin XY; Niu ZC; Han XL; Yang Y; Wei Q; Gao XX; An R; Han LF; Yang WZ; Chai LJ; Liu EW; Gao XM; Mao HP
J Ethnopharmacol; 2021 Apr; 270():113815. PubMed ID: 33444724
[TBL] [Abstract][Full Text] [Related]
9. Casticin suppresses RANKL‑induced osteoclastogenesis and prevents ovariectomy‑induced bone loss by regulating the AKT/ERK and NF‑κB signaling pathways.
Yang F; Su Y; Liang J; Wang K; Lian H; Chen J; Xu J; Zhao J; Liu Q
Int J Mol Med; 2023 May; 51(5):. PubMed ID: 37052260
[TBL] [Abstract][Full Text] [Related]
10. Increased Osteoblastic Cxcl9 Contributes to the Uncoupled Bone Formation and Resorption in Postmenopausal Osteoporosis.
Liu Z; Liang W; Kang D; Chen Q; Ouyang Z; Yan H; Huang B; Jin D; Chen Y; Li Q
Clin Interv Aging; 2020; 15():1201-1212. PubMed ID: 32764906
[TBL] [Abstract][Full Text] [Related]
11. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
[TBL] [Abstract][Full Text] [Related]
12. Cumambrin A prevents OVX-induced osteoporosis
Zhou L; Liu Q; Hong G; Song F; Zhao J; Yuan J; Xu J; Tan RX; Tickner J; Gu Q; Xu J
FASEB J; 2019 Jun; 33(6):6726-6735. PubMed ID: 30807230
[TBL] [Abstract][Full Text] [Related]
13. Tea polysaccharide inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells and ameliorates ovariectomy-induced osteoporosis in rats.
Xu H; Yin D; Liu T; Chen F; Chen Y; Wang X; Sheng J
Biomed Pharmacother; 2018 Jun; 102():539-548. PubMed ID: 29587240
[TBL] [Abstract][Full Text] [Related]
14. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
[TBL] [Abstract][Full Text] [Related]
15. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
[TBL] [Abstract][Full Text] [Related]
16. Effects of JSOG-6 on protection against bone loss in ovariectomized mice through regulation of osteoblast differentiation and osteoclast formation.
Chung HJ; Cho L; Shin JS; Lee J; Ha IH; Park HJ; Lee SK
BMC Complement Altern Med; 2014 Jun; 14():184. PubMed ID: 24903150
[TBL] [Abstract][Full Text] [Related]
17. Hydrogen gas protects against ovariectomy-induced osteoporosis by inhibiting NF-κB activation.
Wu G; Pan L; Sun J; Chen G; Wang S
Menopause; 2019 Jul; 26(7):785-792. PubMed ID: 31083022
[TBL] [Abstract][Full Text] [Related]
18. Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways.
Hsiao HB; Lin H; Wu JB; Lin WC
Osteoporos Int; 2013 May; 24(5):1663-76. PubMed ID: 23143538
[TBL] [Abstract][Full Text] [Related]
19. Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway.
Wu L; Liang J; Li J; Xu Y; Chen J; Su Y; Xian Y; Wei J; Xu J; Zhao J; Liu Q; Yang Y
Eur J Pharmacol; 2022 May; 923():174908. PubMed ID: 35405113
[TBL] [Abstract][Full Text] [Related]
20. Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss.
Peng X; Wang T; Wang Q; Zhao Y; Xu H; Yang H; Gu Y; Tao Y; Yan B; Xu Y; Geng D
Cell Commun Signal; 2024 Mar; 22(1):160. PubMed ID: 38439009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
